CVS Health — Oct 17, 2024 release
Fiscal 2024 third-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001193125-24-239193
Showing in the filing
Medical Benefit Ratio (MBR)
“approximately 95.2%”
Period
Q3 FY2024
Measure
Company-defined measure
Source
Prose
All guidance in this release · 6
Adjusted EPS for Q3 FY2024
“$1.05” – “$1.10”
Adjusted EPS (preliminary) for Q3 FY2024
“$1.05 to $1.10”
GAAP diluted EPS for Q3 FY2024
“$0.03” – “$0.08”
GAAP diluted EPS (preliminary) for Q3 FY2024
“$0.03 to $0.08”
Medical Benefit Ratio (MBR) for Q3 FY2024
“approximately 95.2%”
Weighted average diluted shares outstanding for Q3 FY2024
“1,259”
Exhibit 99.1 · the passage around this item
… earlier in the release
In the third quarter of 2024, the Company has continued to experience medical cost trends in excess of those projected in its prior
outlook. The Medical Benefit Ratio (“MBR”) for the third quarter is currently expected to be approximately 95.2%, which includes a 220-basis point impact from the PDRs. The Company’s
other segments performed consistent with prior projections in the quarter. In light of continued elevated medical cost pressures in the Health Care Benefits segment, investors should no longer rely on the Company’s previous guidance
provided on its second quarter 2024 earnings call on August 7, 2024. The Company plans to further update investors on its third quarter 2024 earnings call, currently scheduled for November 6, 2024, after the company has completed its
standard quarterly close processes. The Company’s preliminary financial results are based on the Company’s current estimate of its results for
the quarter ended September 30, 2024, and remain subject to change based on the completion of closing and review procedures and the execution of the Company’s internal control over financial reporting.
Non-GAAP Financial Measures
This press release includes projected Adjusted EPS, which represents a non-GAAP financial measure. The Company uses non-GAAP financial measures to analyze underlying business performance and trends. The Company believes that providing non-GAAP financial measures enhances the Company’s
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.